|Bid||4.00 x 800|
|Ask||4.46 x 1100|
|Day's Range||4.3000 - 4.6400|
|52 Week Range||3.4490 - 18.1800|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.33|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be awareRead More...
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting IL-27. This program was previously subject to Surface’s collaboration with Novartis. IL-27 is a novel target in immuno-oncology, believed to play a significant and broad role in tumor-related immunosuppression via the regulation of checkpoint protein expression.
- Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT - Surface Oncology will submit an IND for SRF388, a first-in-class IL-27 antibody,.
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific advisory board (SAB). “Surface Oncology continues to grow and learn as a company and we look to align ourselves with world-class leaders in the fields of oncology and immunology. Steve is a clinical pioneer in the field of cancer immunotherapy.
CAMBRIDGE, Mass., Dec. 21, 2018 -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
“A disciplined approach to both drug development and portfolio prioritization is central to our mission to develop truly innovative immunotherapies to help those affected by cancer,” said Jeff Goater, chief executive officer of Surface Oncology.
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president, finance and business operations. She is now responsible for the finance, information technology and facilities functions at Surface. Ms. Fees will also serve as the company’s principal financial and accounting officer, effective December 14, 2018.
In the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.
RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Surface Oncology, Inc. ("Surface Oncology" or the "Company") (NASDAQ: SURF) on behalf of the Company's stockholders. ...
Stocks remained lower Monday afternoon, when the Dow Jones industrial average tumbled, but indexes in general continued to pare losses.
I am going to take a deep dive into Surface Oncology Inc’s (NASDAQ:SURF) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Surface Oncology Inc. (SURF), Synthetic Biologics Inc. (NYSE AMER: SYN), Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO).